Clinical Trial Update: PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating PEG-rhG-CSF (pegfilgrastim) to prevent chemotherapy-induced neutropenia in patients with Non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Pegfilgrastim (pegfilgrastim)

Snippet

Sponsor: Shandong Provincial Hospital | Conditions: Lymphoma,Non-Hodgkin | Phase 4 | Status: UNKNOWN